A real-world study on first-line (1L) treatment for 46 advanced lung adenocarcinoma patients harbouring epidermal growth factor 20 insertion mutation (EGFR ex20ins). - KIVIRID

A real-world study on first-line (1L) treatment for 46 advanced lung adenocarcinoma patients harbouring epidermal growth factor 20 insertion mutation (EGFR ex20ins).

Authors: Mengwei Tian, Xia Zhang, Na Wang, Zhanjun Dou, Xia Song

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e20652

Source: Full article

Abstract

e20652